Tagged with EU

Norway The Top 15 pharmaceutical companies in Norway ranked by sales turnover in 2019. The market is dominated by multinationals, with Novartis, Pfizer and MSD making up the top three positions.   Made with Visme Infographic Maker  

UK US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research Centre’ by 2025.   Having announced that the hub would be built in 2017, one year after the UK’s vote…

Sanofi Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline of BTK inhibitors for autoimmune disorders.   The deal, whereby Sanofi is set to pay USD 100 a share to…

Long Read Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s zesty life science ecosystem. At first glance, the numbers certainly appear more steady than thrilling: a EUR 5.4 billion domestic…

Pharma Faces Belgium is a vitally important country for Johnson & Johnson’s pharmaceutical arm, Janssen, globally. In addition to their R&D centre and a pharma production plant in Beerse, Janssen also has a chemical production plant in Geel, a Clinical Pharmacology Unit in Merksem, and a Phase I research institute in Antwerp…

Belgium Belgium’s healthcare system was ranked fourth in Europe in 2019, outperforming its peers across a number of metrics including a relatively high number of hospital beds per capita (six per thousand citizens, compared to the EU average of five per thousand citizens) and the second-highest number of doctor consultations per…

Sanofi With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe as the new head of its vaccines business unit, Sanofi Pasteur, on June 15th 2020.    Under the watch of CEO Paul Hudson, appointed at the end of 2019, Sanofi has initiated…

Europe In conversation with PharmaBoardroom Christoph Stoller and Adrian Van den Hoven of Medicines for Europe, the association representing the European generics, biosimilar and value-added-medicines industry, highlighted their members’ rapid response to the COVID-19 crisis and why Europe-wide reform is needed to avoid future medicine shortages and strengthen the supply chain.…

Belgium Serge Kemps, CEO of Nipro Medical Europe, sits down with PharmaBoardroom to shed light on Nipro’s unique corporate culture based on the Japanese concept of ‘sanpro yoshi’. Kemps also explains the importance of Belgium for Nipro, the innovation opportunities in the digitalisation of healthcare, and his strategic priorities since taking…

Medicines for Europe In the wake of the publication of Medicines for Europe’s Lessons Learned from COVID-19 policy paper, Christoph Stoller & Adrian van den Hoven outline the European generics, biosimilar and value-added-medicines industry’s rapid and comprehensive response to the COVID-19 crisis as well as the potential long-term shifts in European pharmaceutical policy…

Novartis In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) to Pia Boehnke, a Belgian child.   With Zolgensma® at that point having not yet been authorised by the European…

GSK GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom recently spoke to Emmanuel Hanon, GSK’s senior VP for vaccines R&D, to get his take on the company’s unique role…